调节CGRP信号:一种有希望的治疗途径,用于减轻心力衰竭中的心脏功能障碍
Shazia Ansari1, Khadga Raj Aran2,3
1Department of Pharmacy Practice, ISF College of Pharmacy, Punjab, 142001, Moga, India.
Cardiovascular drugs and therapy
|January 17, 2026
概括
素基因相关 (CGRP) 通过调节心血管平衡,在心力衰竭 (HF) 中发挥关键作用. 针对CGRP的疗法有望改善HF结果,但安全性评估至关重要.
科学领域:
- 心脏病学 心脏病学
- 神经内分泌学神经内分泌学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心力衰竭 (HF) 是一种复杂的综合症,患病率和死亡率很高.
- 素基因相关 (CGRP) 对于心血管平衡至关重要,提供血管扩张,心脏保护和抗炎作用.
- CGRP对抗有害的神经激素系统,如高频的RAAS和SNS.
研究的目的:
- 审查CGRP在心力衰竭中的生理和病理生理作用.
- 评估针对高频率的CGRP信号的治疗策略.
- 讨论基于CGRP的HF管理的未来方向.
主要方法:
- 对高频率CGRP的临床前和临床研究的文献综述.
- 分析CGRP在不同高压阶段和患者子组中的作用.
- 对CGRP向疗法的评估和安全考虑.
主要成果:
- 早期的HF受益于高CGRP,但渐进阶段显示CGRP耗尽和信号受损.
- 针对CGRP信号的治疗策略显示出有希望的临床前和早期临床结果.
- 在特定HF人群中观察到的潜在益处 (NYHA I-III,HFpEF,高血压/缺血驱动的HF).
结论:
- 在HF病原和进展中,CGRP通路至关重要.
- 准CGRP为HF管理提供了有前途的治疗途径.
- 需要进一步研究患者分层,生物标志物导向治疗和安全性评估,尤其是CGRP对抗剂.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Heart Failure Drugs: Inotropic Agents
1.3K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.3K
Heart Failure Drugs: β-Blockers
772
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
772
Cardiomyopathy V: Interprofessional Care
339
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
G-Protein Gated Ion Channels
5.6K
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory...
Sensory...
5.6K


